More on Merck Q1: Net profit +7%

Merck (MRK) net profit rises to $1.705B from $1.59B a year earlier

Revenues hurt by patent expirations and currency fluctuations.

Pharmaceuticals revenues -4.7% to $8.45B, dragged down by generic competition for Merck's Singulair treatment for allergy and asthma; consumer care -4.4%; animal-health -3.2%.

Sales of Remicade, Simponi and Isentress, as well as of Diabetes and Vaccines Franchises, grew.

Affirms FY guidance for adjusted EPS of $3.35-3.53 vs consensus of $3.45.

Shares +1.45% premarket. (PR)


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs